Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

New ophthalmic gene licensed by InSite

Feb. 10, 2000

Oculex updates intraocular drug delivery pipeline

Feb. 4, 2000

Visudyne market introduction announced

Feb. 2, 2000

Are cannabinoid receptors involved in the IOP-lowering effects of cannabinoids?

Feb. 2, 2000

InSite Vision licenses novel TIGR modifier gene

Feb. 2, 2000

Alcon makes milestone payment to Pharmacyclics for Optrin

Feb. 1, 2000

KeraVision commences clinical trials for use of Intacs as treatment of keratoconus

Jan. 19, 2000

Pharmacia & Upjohn seeks approval for combination glaucoma therapy

Jan. 11, 2000

Inspire's dry eye product enters phase II testing

Jan. 10, 2000

Allergan's therapy for allergic conjunctivitis approved for U.S. marketing

Dec. 27, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....